View Item 

Show simple item record

Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemir

dc.contributor.authorBryant, Ginelle A.en_US
dc.contributor.authorMcDanel, Deanna L.en_US
dc.contributor.authorHorner, Kathleen E.en_US
dc.contributor.authorFarris, Karen B.en_US
dc.contributor.authorNewkirk, Erin N.en_US
dc.date.accessioned2013-02-12T19:00:58Z
dc.date.available2014-03-03T15:09:24Zen_US
dc.date.issued2013-01en_US
dc.identifier.citationBryant, Ginelle A.; McDanel, Deanna L.; Horner, Kathleen E.; Farris, Karen B.; Newkirk, Erin N. (2013). "Evaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemir." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy (1): 56-62. <http://hdl.handle.net/2027.42/96348>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/96348
dc.publisherWiley Periodicals, Inc.en_US
dc.subject.otherLong‐Acting Insulinen_US
dc.subject.otherDetemiren_US
dc.subject.otherGlargineen_US
dc.subject.otherInsulin Dose Conversionen_US
dc.subject.otherBasal Insulinen_US
dc.titleEvaluation of Dosing and Clinical Outcomes in Patients Undergoing Conversion of Insulin Glargine to Insulin Detemiren_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid23307546en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/96348/1/phar1168.pdf
dc.identifier.doi10.1002/phar.1168en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceSwinnen SGHA, Hans DeVries J. Higher dose requirements with insulin detemir in type 2 diabetes—three cases and a review of the literature. Diabetes Res Clin Pract 2009; 84: e24 – 6.en_US
dc.identifier.citedreferenceUK Prospective Diabetes Study (UKPDS‐33). Intensive blood‐glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837 – 53.en_US
dc.identifier.citedreferenceDiabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long‐term complications in insulin‐dependent diabetes mellitus. N Engl J Med 1993; 329: 977 – 86.en_US
dc.identifier.citedreferenceNathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005; 353: 2643 – 53.en_US
dc.identifier.citedreferenceStratton IM, Alder AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405 – 12.en_US
dc.identifier.citedreferenceAmerican Diabetes Association. Standards of medical care in diabetes—2012. Diabetes Care 2012; 35 ( 1 ): S11 – 63.en_US
dc.identifier.citedreferenceSanofi‐Aventis. Lantus (insulin glargine) prescribing information. Bridgewater, NJ; 2007.en_US
dc.identifier.citedreferencePharmacist's Letter/Prescriber's Letter. Comparison of insulins and injectable diabetes meds. PL Detail‐Document #281107 November 2012. Available at www.PharmacistsLetter.com. Acessed December 6, 2012.en_US
dc.identifier.citedreferenceNovo Nordisk Inc. Levemir [insulin detemir] prescribing information. Princeton, NJ; 2005.en_US
dc.identifier.citedreferenceBell DSH. Insulin therapy in diabetes mellitus: how can the currently available injectable insulins be most prudently and efficaciously utilized? Drugs 2007; 67 ( 13 ): 1813 – 27.en_US
dc.identifier.citedreferencePlank J, Bodenlenz M, Sinner F, et al. A double‐blind, randomized, dose‐response study investigating the pharmacodynamic and pharmacokinetic properties of the long‐acting insulin analog detemir. Diabetes Care 2005: 28 ( 5 ): 1107 – 12.en_US
dc.identifier.citedreferenceDrugstore.com. Levemir (detemir); Lantus (glargine). Available from www.drugstore.com. Accessed December 12, 2011.en_US
dc.identifier.citedreferenceMeneghini LF, Rosenberg KH, Koenen C, Merilainen MJ, Luddeke HJ. Insulin detemir improves glycaemic control with less hypoglycemia and no weight gain in patients with type 2 diabetes who were insulin naïve or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007; 9 ( 3 ): 418 – 27.en_US
dc.identifier.citedreferencePieber TR, Treichel HC, Hompesch B, et al. Comparison of insulin detemir and insulin glargine in subjects with type 1 diabetes using intensive insulin therapy. Diabetes Med 2007; 24: 635 – 42.en_US
dc.identifier.citedreferenceRosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G. A randomized, 52‐week, treat‐to‐target trial comparing insulin detemir with insulin glargine when administered as add‐on to glucose‐lowering drugs in insulin‐naïve people with type 2 diabetes. Diabetologia 2008; 51: 408 – 16.en_US
dc.identifier.citedreferenceKabadi U. Deleterious outcomes after abrupt transition from insulin glargine to insulin detemir in patients with type 1 diabetes mellitus. Clin Drug Invest 2008; 28 ( 11 ): 697 – 701.en_US
dc.identifier.citedreferenceHollander P, Cooper J, Bregnhj J, Pedersen CB. A 52‐week, multinational, open‐label, parallel‐group, noninferiority, treat‐to‐target trial comparing insulin detemir with insulin glargine in a basal‐bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. Clin Ther 2008; 30: 1976 – 87.en_US
dc.identifier.citedreferenceDeVries JH, Nattrass M, Pieber TR. Refining basal insulin therapy: what have we learned in the age of analogues? Diab Metab Res Rev 2007; 23: 441 – 54.en_US
dc.identifier.citedreferenceAlbright ES, Desmond R, Bell DS. Efficacy of conversion from bedtime NPH insulin injection to once‐ or twice‐daily injections of insulin glargine in type 1 diabetic patients using basal/bolus therapy. Diabetes Care 2004; 27: 632 – 3.en_US
dc.identifier.citedreferenceAshwell SG, Gebbie J, Home PD. Twice‐daily compared with once‐daily insulin glargine in people with type 1 diabetes using meal‐time insulin aspart. Diabetes Med 2006; 23: 879 – 86.en_US
dc.identifier.citedreferenceDaily G, Admane K, Mercier F, Owens D. Relationship of insulin dose, A1c lowering, and weight in type 2 diabetes: comparing insulin glargine and insulin detemir. Diabetes Technol Ther 2010; 12 ( 12 ): 1019 – 27.en_US
dc.identifier.citedreferenceHermansen K, Madsbad S, Perrild H, Kristensen A, Axelsen M. Comparison of the soluble basal insulin analog insulin detemir with NPH insulin: a randomized open crossover trial in type 1 diabetic subjects on basal‐bolus therapy. Diabetes Care 2001; 24 ( 2 ): 296 – 301.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phar1168.pdf
Size:
59.53KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.